Overall, while monoclonal antibodies to RANKL, Sclerostin, and DKK-1 for the treatment of osteoporosis are approved or in clinical trials, there is still a lack of knowledge regarding how to use these drugs effectively and which biomarkers must influence therapy selection. This evidence concerns the gene SOST and osteoporosis.